Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Risk of Chronic Obstructive Pulmonary Disease Exacerbation in Patients Who Use Methotrexate-A Nationwide Study of 58,580 Outpatients

Research output: Contribution to journalJournal articleResearchpeer-review

  1. The Importance of Lipoprotein Lipase Regulation in Atherosclerosis

    Research output: Contribution to journalReviewResearchpeer-review

  2. Efficacy and Mode of Action of Mesenchymal Stem Cells in Non-Ischemic Dilated Cardiomyopathy: A Systematic Review

    Research output: Contribution to journalReviewResearchpeer-review

  3. The Phenotypic Spectrum of PRRT2-Associated Paroxysmal Neurologic Disorders in Childhood

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Identification of Novel Native Autoantigens in Rheumatoid Arthritis

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Patients with severe chronic obstructive pulmonary disease (COPD) experience frequent acute exacerbations and require repeated courses of corticosteroid therapy, which may lead to adverse effects. Methotrexate (MTX) has anti-inflammatory properties. The objective of this study was to describe the risk of COPD exacerbation in patients exposed to MTX. In this nationwide cohort study of 58,580 COPD outpatients, we compared the risk of hospitalization-requiring COPD exacerbation or death within 180 days in MTX vs. non-MTX users in a propensity-score matched study population as well as an unmatched cohort, in which we adjusted for confounders. The use of MTX was associated with a reduction in risk of COPD exacerbation in the propensity-score matched population at 180 days follow-up (HR 0.66, CI 0.66-0.66, p < 0.001). Similar results were shown in our sensitivity analyses at 180-day follow-up on unmatched population and 365-day follow-up on matched and unmatched population (HR 0.76 CI 0.59-0.99, HR 0.81 CI 0.81-0.82 and HR 0.92 CI 0.76-1.11, respectively). MTX was associated with a lower risk of COPD exacerbation within the first six months after study entry. The finding seems biologically plausible and could potentially be a part of the management of COPD patients with many exacerbations.

Original languageEnglish
Article number604
JournalBiomedicines
Volume9
Issue number6
ISSN2227-9059
DOIs
Publication statusPublished - Jun 2021

    Research areas

  • Airway inflammation, Anti-inflammatory, Chronic obstructive pulmonary disease, Exacerbation of chronic obstructive pulmonary disease, Immunosuppression

ID: 66309620